Insulin aspart Sanofi Uniunea Europeană - islandeză - EMA (European Medicines Agency)

insulin aspart sanofi

sanofi winthrop industrie - insúlín aspart - sykursýki - lyf notuð við sykursýki - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Imcivree Uniunea Europeană - islandeză - EMA (European Medicines Agency)

imcivree

rhythm pharmaceuticals netherlands b.v. - setmelanotide - offita - Ónæmiskerfi, þó ekki mataræði - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Kirsty (previously Kixelle) Uniunea Europeană - islandeză - EMA (European Medicines Agency)

kirsty (previously kixelle)

biosimilar collaborations ireland limited - insúlín aspart - sykursýki - lyf notuð við sykursýki - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Uniunea Europeană - islandeză - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hinsveiflur og heilahimnubólur og hliðstæður - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Dapagliflozin Viatris Uniunea Europeană - islandeză - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lyf notuð við sykursýki - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Narcostop Stungulyf, lausn 5 mg/ml Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

narcostop stungulyf, lausn 5 mg/ml

le vet b.v.* - atipamezolum hýdróklóríð - stungulyf, lausn - 5 mg/ml

Flexbumin Innrennslislyf, lausn 200 g/l Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

flexbumin innrennslislyf, lausn 200 g/l

baxalta innovations gmbh - human serum albumin - innrennslislyf, lausn - 200 g/l

Lederspan Stungulyf, dreifa 20 mg/ml Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

lederspan stungulyf, dreifa 20 mg/ml

viatris aps - triamcinolonum hexacetóníð - stungulyf, dreifa - 20 mg/ml

Propolipid Stungulyf/innrennslislyf, fleyti 10 mg/ml Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

propolipid stungulyf/innrennslislyf, fleyti 10 mg/ml

fresenius kabi ab - propofolum inn - stungulyf/innrennslislyf, fleyti - 10 mg/ml